早期非小细胞肺癌的管理:美国胸科医师学会临床实践指南
该CHEST指南基于578项研究,针对I/II期非小细胞肺癌原发治疗制定17条推荐。I期可手术患者首选手术切除,I期优选微创入路;外周≤2 cm肿瘤亚肺叶切除与肺叶切除总生存相当;不适合手术的I期患者首选立体定向体部放疗;II期切除后辅助化疗联合检查点抑制剂、IB(≥3 cm)及II期EGFR突变术后辅助靶向治疗可改善总生存。
要点
- I期NSCLC平均或低手术风险患者最佳治疗仍为手术切除,微创入路优于开胸。
- 外周≤2 cm的I期NSCLC,亚肺叶切除与肺叶切除总生存相当。
- 不适合手术的I期NSCLC患者,立体定向体部放疗是首选方法。
核心结论
- I期NSCLC可手术患者首选手术切除,微创入路优于开胸。
- 外周≤2 cm的I期NSCLC亚肺叶切除与肺叶切除总生存相当。
- 不适合手术的I期NSCLC患者首选立体定向体部放疗。
- II期切除后辅助化疗联合检查点抑制剂可改善总生存。
- IB(≥3 cm)及II期EGFR突变术后辅助靶向治疗可改善总生存。
研究设计与样本
- 美国胸科医师学会组织专家组制定,采用系统评价和GRADE方法评估证据 certainty 与推荐强度,改良Delphi法达成共识。
- 基于578项研究制定17条推荐。
主要发现
- Meta分析显示I期肺癌微创手术与更好的患者结局相关。
- 新证据显示外周≤2 cm的NSCLC亚肺叶切除与肺叶切除总生存相当。
- II期切除后辅助化疗联合检查点抑制剂(包括≥4 cm、淋巴结阴性肿瘤)改善总生存。
- IB(≥3 cm)和II期EGFR突变肺癌切除后辅助靶向治疗改善总生存。
关键数值与推荐
- I期NSCLC平均或低手术风险患者推荐手术切除。
- I期NSCLC推荐微创入路优于开胸。
- 外周≤2 cm的I期NSCLC可考虑亚肺叶切除。
- I/II期NSCLC手术时应进行系统性纵隔和肺门淋巴结采样或清扫。
- 不适合手术的I期NSCLC推荐立体定向体部放疗。
临床怎么用
- I期NSCLC可手术患者应优先选择微创手术切除。
- 外周≤2 cm的I期NSCLC可与患者讨论亚肺叶切除。
- 手术中需进行系统性纵隔和肺门淋巴结采样或清扫。
- II期切除后考虑辅助化疗联合检查点抑制剂。
- IB(≥3 cm)及II期EGFR突变术后考虑辅助靶向治疗。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Lung cancer remains the number 1 cause of cancer death in men and women in the United States and much of the world. This CHEST organization guideline examines the literature on primary treatment of patients with stage I and II non-small cell lung cancer (NSCLC) to provide evidence-based recommendations. STUDY DESIGN AND METHODS: An expert panel conducted a systematic review addressing the treatment options for patients with stage I/II NSCLC and applied the Grading of Recommendations, Assessment, Development, and Evaluations approach for assessing the certainty of evidence and grading of recommendations. A modified Delphi approach was used to reach consensus on recommendations. RESULTS: Based on 578 studies, the panel developed 17 recommendations. INTERPRETATION: The best treatment for average or low operative risk patients with stage I NSCLC remains surgical resection. In patients with stage I NSCLC, a minimally invasive approach is preferred over thoracotomy. For the first time, a meta-analysis comparing overall survival for patients with stage I lung cancer reveals an association between minimally invasive surgery and better patient outcomes. New evidence reveals equivalent overall survival for patients with peripheral ≤ 2 cm NSCLC treated with a sublobar resection compared with lobectomy. To have confidence in the generalizability of these trials, it is important to perform systematic intraoperative mediastinal and hilar lymph node sampling or dissection during operations for patients with stage I and II NSCLC. Use of adjuvant chemotherapy in patients with resected stage II NSCLC plus checkpoint inhibitors, including those patients with ≥ 4 cm, node-negative tumors, improves overall survival. In patients with resected stage IB (≥ 3 cm) and II epidermal growth factor receptor mutant lung cancers, adjuvant targeted therapy improves overall survival. Stereotactic body radiotherapy is the preferred approach to patients with stage I NSCLC who are not considered appropriate candidates for surgical resection.
引用
- Howington J, Souter LH, Arenberg D, et al. Management of Patients With Early-Stage Non-Small Cell Lung Cancer: An American College of Chest Physicians Clinical Practice Guideline. Chest. 2025. PMID: 40562304. doi:10.1016/j.chest.2025.06.023
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。